Close Menu


Support for Another

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

CNN reports Johnson & Johnson is seeking an emergency authorization for its SARS-CoV-2 vaccine in the US.

Johnson & Johnson says its candidate SARS-CoV-2 vaccine has 66 percent efficacy rate in preventing moderate-to-severe COVID-19, according to NPR.

Johnson & Johnson reports interim results from a Phase 1/2 study of its SARS-CoV-2 vaccine in the New England Journal of Medicine, according to Bloomberg.

The Universities of Southampton and Leeds will lead the project with participation from Johnson & Johnson, Roche, Oncimmune, BC Platforms, Inivata, and NHS England.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

And Resumed

Two coronavirus vaccine trials that had been paused in the US have resumed.

To Get Back Going

The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

A Different Pause

Stat News reports Johnson & Johnson has paused its SARS-CoV-2 vaccine trial due to an unexplained illness affecting a study participant.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.


Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.